Douglas E. Coltharp sells 12,260 shares of Encompass Health Co. (NYSE:EHC)

Encompass Health Co. (NYSE:EHC – Get Your Free Report ) CFO Douglas E. Coltharp sold 12,260 shares of the business’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $86.34, for a total value of $1,058,528.40. Following the transaction, the chief financial officer now directly owns 136,227 shares of the company’s stock, valued at $11,761,839.18. The sale was disclosed in a filing with the SEC, which can be accessed via this hyperlink.

Encapsulates health stock performance

Shares of EHC stock opened at $89.28 on Friday. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.37, and a quick ratio of 1.37. The stock has a 50-day moving average of $86.69 and a 200-day moving average of $81.97. The company has a market cap of $8.99 billion, a PE ratio of 24.13, a P/E/G ratio of 1.45 and a beta of 0.89. Encompass Health Co. has a one year low of $57.55 and a one year high of $94.38.

Encompass Health (NYSE:EHC – Get Free Report ) last posted its earnings results on Monday, August 5th. The company reported $1.11 EPS for the quarter, topping the consensus estimate of $1.01 by $0.10. The company had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.30 billion. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period last year, the business posted EPS of $0.95. On average, equities research analysts predict that Encompass Health Co. will post 4.09 EPS for the current fiscal year.

Embed health increases dividends

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Tuesday, October 1st will be paid a dividend of $0.17 per share. The ex-dividend date is Tuesday, October 1st. This represents a dividend of $0.68 on an annualized basis and a yield of 0.76%. This is an increase from Encompass Health’s previous quarterly dividend of $0.15. Encompass Health’s payout ratio is 18.38%.

Hedge funds influence health

Hedge funds have recently added to or reduced their holdings in the stock. Principal Securities Inc. purchased a new position in Encompass Health in the 4th quarter valued at about $25,000. Benjamin F. Edwards & Company Inc. raised its stake in Encompass Health by 360.2% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 405 shares of the company’s stock valued at $27,000 after buying an additional 317 shares in the last quarter. GAMMA Investing LLC purchased a new position in Encompass Health in the 4th quarter valued at about $33,000. Parallel Advisors LLC grew its stake in Encompass Health by 192.3% in the 4th quarter. Parallel Advisors LLC now owns 573 shares of the company’s stock worth $38,000 after buying an additional 377 shares in the last quarter . Finally, Oakworth Capital Inc. purchased a new position in shares of Encompass Health in the second quarter valued at approximately $40,000. Institutional investors and hedge funds own 97.25% of the company’s shares.

Analyst upgrades and downgrades

Several brokerages have recently issued reports on EHC. Stephens reaffirmed an “overweight” rating and set a $105.00 target price on shares of Encompass Health in a research report on Tuesday, August 6th. Leerink Partners raised Encompass Health to a “strong-buy” rating in a research report on Wednesday, July 10th. UBS Group lifted their price objective on Encompass Health from $96.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Truist Financial lifted their price objective on Encompass Health from $100.00 to $104.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Royal Bank of Canada lifted their price objective on Encompass Health from $83.00 to $95.00 and gave the stock an “outperform” rating in a research report on Wednesday, the 22nd May. Nine analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $100.38, based on data from MarketBeat.

Read our latest review of EHC

Encompass Health Company Profile

(Get a free report)

Encompass Health Corporation provides post-acute care services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy and ancillary services. The Company provides specialized inpatient rehabilitation treatment to patients who have suffered physical or cognitive disabilities or injuries due to medical conditions such as strokes, hip fractures and various debilitating neurological conditions.

Featured stories

Get news and reviews for Encompass Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Encompass Health and related companies with MarketBeat.com’s FREE daily email newsletter.